QUANTUM PHARMA GROUP LIMITED

Company number 06775418 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Investment Risk Analysis: QUANTUM PHARMA GROUP LIMITED

Companies House Number: 06775418 Analysis Date: Based on available filing data


1. Risk Rating: MEDIUM

Justification: This entity presents as a holding company (SIC 70100 - Activities of head offices) operating within a corporate group structure. While the company is active and filings are current, the limited financial visibility inherent to its subsidiary audit exemption status, combined with a recent director resignation and opaque group structure, warrants a measured risk assessment. The absence of financial statement data prevents a definitive solvency or liquidity determination.


2. Key Concerns

i. Financial Transparency Limitations

The company files under "Audit Exemption Subsidiary" status, meaning it relies on parent company group accounts for audit purposes. This significantly limits visibility into the entity's standalone financial position. No balance sheet, P&L, or cash flow data is available in the provided records, making independent solvency and liquidity assessment impossible from this dataset alone.

ii. Recent Director Departure

name shown to subscribers resigned as director on 2026-10-05, which is a relatively recent governance event. While director changes occur for many legitimate reasons, a departure from a holding company board warrants investigation into the circumstances—particularly whether it signals strategic disagreement, financial distress at the group level, or simply planned succession.

iii. Complex/Opaque Ownership Structure

The PSC register lists "Quantum Pharma 2014 Limited" twice as a corporate entity with significant influence or control. The duplicate entry may be an administrative error or reflect multiple control mechanisms (e.g., shareholding and voting rights separately disclosed). The ultimate beneficial ownership chains upward from Quantum Pharma 2014 Limited are not visible in this dataset, creating uncertainty about who ultimately controls the group.


3. Positive Indicators

  • Filing Compliance: Both annual accounts (next due 2027-03-31) and confirmation statements (next due 2026-12-25) are current and not overdue, indicating basic regulatory compliance is being maintained.
  • Corporate Longevity: Incorporated in December 2008, the company has maintained active status for approximately 17 years, suggesting operational continuity and survival through multiple economic cycles.
  • Stable Registered Presence: The company maintains a registered address at 25 Bedford Square, Bloomsbury, London—a established commercial location rather than a virtual office or residential address.
  • Established Group Structure: The name change from "Hamsard 3149 Limited" in 2015 to "Quantum Pharma Group Limited" suggests a deliberate rebranding or acquisition event that formalised the pharmaceutical focus, indicating strategic intent rather than a shell entity.

4. Due Diligence Notes

Financial Investigation Required

  • Obtain consolidated group accounts: The parent entity (likely Quantum Pharma 2014 Limited or above) should file consolidated accounts that include this subsidiary's financials. These should be requested and reviewed for solvency indicators, working capital position, and profitability trends.
  • Verify share capital: Recorded share capital of £396,652 should be reconciled against the group's capital structure and any recent share issuances or buybacks.

Governance Investigation

  • Clarify PSC duplication: Confirm whether the duplicate PSC entry for Quantum Pharma 2014 Limited is a filing error or reflects distinct control mechanisms. Trace the ownership chain to identify ultimate beneficial owners.
  • Investigate director resignation: Establish the reason for name shown to subscribers's departure (October 2026) and whether any related governance concerns exist. Review any corresponding changes at the parent or sister company level.
  • Review director disqualification records: The provided data does not indicate any disqualifications, but this should be formally verified against the Insolvency Service database for all current and recent officers.

Operational Assessment

  • Map the group structure: Identify all subsidiaries within the Quantum Pharma group, their trading activities, and intercompany transactions. Given the SIC code 70100, this entity likely does not trade directly but holds investments or manages group operations.
  • Assess pharmaceutical sector exposure: Understand the specific pharmaceutical activities within the group—whether manufacturing, distribution, licensing, or R&D—as each carries different regulatory and commercial risk profiles.
  • Review historical financials: Obtain up to 10 years of filed accounts (where available) to assess trend stability, any prior periods of loss, or balance sheet deterioration.

Regulatory Compliance

  • Confirm audit exemption validity: Verify that the parent company genuinely provides a guarantee under Section 479C of the Companies Act 2006, which is the statutory basis for subsidiary audit exemption. Failure to maintain this guarantee would invalidate the exemption.
  • Check for associated entities: Search for other companies with shared officers or addresses that may indicate related-party transactions not visible from this entity's filings alone.

Names of the people mentioned are shown to subscribers. See subscription

Perspective: Investment Risk Assessor · Model: glm-5.2 · Generated 16 October 2026